Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.

Eli Lilly (NYSE:LLY) has decided to stop one of its obesity drug combination trials, pressing pause on a study that paired ...

US pharma major Eli Lilly has halted a study of an experimental drug, bimagrumab, designed to prevent obesity patients from ...

Excellus BlueCross BlueShield is pushing back against reports that it will no longer cover GLP-1 medications, saying drugs used to treat certain medical conditions remain ...

Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

LONDON (Reuters) -AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients ...

Dr. Eithan Haim has said publicly that he leaked the documents to a conservative activist in 2023 to “expose” care that he ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop ...

Fractyl Health (GUTS) announced on Friday that patients who stopped taking the GLP-1 class drug Tirzepatide and were treated ...

President Donald Trump unveiled a slew of new tariffs, including 100% levies on pharmaceuticals imports, but exempted drug ...

The researchers found that, compared to the AGHE, the Mediterranean diet resulted in a significant decrease in waist ...